|9th September 2020||Andy Sassine||10,000||Open or private sale||$9.47||$94,746.00|
|8th September 2020||Andy Sassine||10,000||Open or private sale||$9.40||$93,977.00|
|1st September 2020||R. Scott Areglado||5,000||Open or private sale||$10.49||$52,431.00|
|1st September 2020||Stacey M Stevens||24,127||Open or private sale||$10.25||$247,407.91|
|1st September 2020||Stacey M Stevens||24,127||Exercise of derivative||$2.27||$54,768.29|
|7th August 2020||Andy Sassine||10,000||Open or private sale||$10.28||$102,821.00|
|6th August 2020||Andy Sassine||10,000||Open or private sale||$10.31||$103,079.00|
|5th August 2020||Stacey M Stevens||6,667||Open or private sale||$10.07||$67,146.69|
|5th August 2020||Stacey M Stevens||6,667||Exercise of derivative||$2.90||$19,334.30|
|15th July 2020||Stacey M Stevens||10,000||Open or private sale||$10.25||$102,490.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 7/10.
iCAD, Inc. engages in the provision of advanced image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer. It operates through the Cancer Detection and Cancer Therapy business segments. The company was founded in 1984 and is headquartered in Nashua, NH.